Skip to content
Menu

MoonLake Immunotherapeutics MLTX

Full chart Compare
Set alert

Price alert · MLTX

All alert types
11.03 USD +0.24 (+2.22%)

Regular-session close

11.24 +0.21 +1.90%

Pre-market · Nov 20, 7:57 AM ET

10.85 Day range 11.69
9.46 52-week range 23.29
YTD
-16.31%
1 year
-18.54%

5D -1.51 (-12.04%)

111213FriMonTueWedThu11.03
Market cap
938.73M
EPS (ttm)
-3.66
Shares out
85.11M
Forward P/E
-3.68
YTD return
-16.31%
1-year return
-18.54%
50-day average
11.93
200-day average
16.28
Enterprise value
698.48M
Price / book
2.79
Volume
1.41M
Avg volume
1.64M
Open
10.90
Previous close
10.79
Day's range
10.85 – 11.69
52-week range
9.46 – 23.29
Beta
1.13
Analysts
Buy
Price target
30.29 (+174.6%)
Earnings date
Feb 24, 2027

Key statistics

Free cash flow
-146.75M
Total cash
498.46M
Total debt
101.62M
Return on equity
-81.47%
Short % of float
8.87%

Fundamental scorecard

4 of 25 checks passed on MLTX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MLTX Revenue — quarterly 0
MLTX Net income — quarterly -79.55M
MLTX EPS — quarterly -0.93

Earnings

MLTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-0.84———
Nov 4, 2026Sep 30, 2026-0.83257-0.93-0.10-11.70%
Aug 10, 2026Jun 30, 2026-0.90859-0.84+0.07+7.55%
May 11, 2026Mar 31, 2026-0.91-0.98-0.07-7.69%
Feb 25, 2026Dec 31, 2025-0.92-0.920.000.00%
Nov 5, 2025Sep 30, 2025-0.89-1.10-0.21-23.60%

Upgrades / downgrades

MLTX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 5, 2026HC Wainwright & Co.reitBuyBuy
Aug 13, 2026HC Wainwright & Co.mainBuyBuy
Jul 20, 2026HC Wainwright & Co.reitBuyBuy
Jul 1, 2026Leerink PartnersmainOutperformOutperform
Jun 9, 2026BTIGreitBuyBuy
Jun 8, 2026HC Wainwright & Co.reitBuyBuy

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland

News

Your note

Sign in to keep a note on MLTX — it syncs with the Stock Master app.

Insider holders

MLTX insider holders
InsiderRelationLatest transactionDateShares held
BODENSTEDT MATTHIASChief Financial OfficerSaleJun 21, 20261,115,440
BVF PARTNERS L PBeneficial Owner of more than 10% of a Class of SecuritySaleMar 30, 20260
CHEN BIHUA X.FormerSaleSep 29, 20250
MOUKHEIBIR CATHERINEDirectorSaleJul 2, 20250
REICH KRISTIANOfficerSaleJul 26, 20260
SANTOS DA SILVA JORGEChief Executive OfficerSaleJul 9, 20262,774,890

Institution ownership

MLTX institution ownership
Holder% heldSharesValueReported
BVF Inc.18.80%16,001,284200.02MJun 29, 2026
Deep Track Capital, Lp8.22%6,999,02587.49MJun 29, 2026
T. Rowe Price Investment Management, Inc.5.03%4,280,62453.51MJun 29, 2026
Shaw D.E. & Co., Inc.3.95%3,365,50742.07MJun 29, 2026
Cormorant Asset Management, LP3.77%3,205,43340.07MJun 29, 2026
Jupiter Topco LLC3.63%3,085,90638.57MJun 29, 2026

Fund ownership

MLTX fund ownership
Holder% heldSharesValueReported
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App1.90%1,614,28920.18MJun 29, 2026
T. Rowe Price Small-Cap Value Fund, Inc.1.08%918,58611.48MJun 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.93%792,0729.90MJun 29, 2026
TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust0.71%605,4747.57MJun 29, 2026
JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund0.41%350,1344.38MJun 29, 2026
T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq0.20%167,7682.10MJun 29, 2026